Identifíquese
¿Aún no es suscriptor de la revista?
Comprar el acceso al artículo
Comprando el artículo el pdf del mismo podrá ser descargado
Teléfono para incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
Bibliografía
[1]
Aspectos clínicos de la insuficiencia cardíaca: insuficiencia cardíaca con gasto cardíaco elevado y edema pulmonar. En: Braunwald E, Zipes DP, Lobby P, editores. Braunwald's Cardiología. El libro de Medicina Cardiovascular (6.ª ed). Philadelphia: 2001. p. 652-88.
[2]
Killip T, Kimball JT..
Treatment of myocardial infarction in a coronary care unit..
Am J Cardiol, (1967), 20 pp. 457-64
[3]
Bersten AD, Holt AW, Vedig EA..
Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask..
N Engl J Med, (1991), 325 pp. 1825-30
[4]
Masip J, Betbese AJ, Paez J, Vecilla F, Canizares R, Padro J, et al..
Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema:a randomised trial. Lance, (2000), 356 pp. 2126-32
[5]
Masip J..
Ventilación mecánica no invasiva en el edema agudo de pulmón..
Rev Esp Cardiol, (2001), 54 pp. 1023-8
[6]
Mehta S, Jay GD, Woolard RH, Hipona RA, Connolly EM, Cimini DM, et al..
Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary oedema..
Crit Care Med, (1997), 25 pp. 620-8
[7]
Hsu HO, Hickey RF, Forbes AR..
Morphine decreases peripheral vascular resistance and increases capacitance in man..
Anesthesiology, (1979), 50 pp. 98-102
[8]
Anand IS, Florea VG..
Diuretics in chronic heart failure benefits and hazards..
Eur Heart J, (2001), Suppl3 pp. G8-18
[9]
Tratamiento farmacológico de la insuficiencia cardíaca. En: Hardman JG, Limbird LE, editores. Goodman & Gillman. Las bases farmacológicas de la terapéutica. 10.ª edición. Méjico: 2002. p. 911-42.
[10]
Schuller D, Lynch JP, Fine D..
Protocol-guided diuretic management: comparison of furosemide by continuos infusion and intermittent bolus..
Crit Care Med, (1997), 25 pp. 1969-75
[11]
Dormans TP, Van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P..
Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continous infusion..
J Am Coll Cardiol, (1996), 283 pp. 76-82
[12]
Licata G, Di Pascuale P, Parrinello G, Cardinale A, Scandurra A, Follone G, et al..
Effects of high dose furosemide and small volume hypertonic saline solution infusion in comparison in refractary congestive heart failure: long-term effects..
Am Heart J, (2003), 145 pp. 459-66
[13]
Johnson W, Omland T, Hall C, Lucas C, Myking OL, Collins C, et al..
Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure..
J Am Coll Cardiol, (2002), 39 pp. 1623-9
[14]
Kramer BK, Schweda F, Riegger GA..
Diuretic treatment and diuretic resistance in heart failure..
Am J Med, (1999), 106 pp. 90-96
[15]
Cohn JN, Franciosa JA, Francis GS, Archibald D, Tristani F, Fletcher R, et al..
Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study..
N Engl J Med, (1982), 306 pp. 1929-35
[16]
Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Smovitz A, et al..
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema..
Lancet, (1998), 351 pp. 389-93
[17]
Tamargo J, López-Sendón J, Delpón E..
Nuevos fármacos en el tratamiento de la insuficiencia cardíaca aguda..
Monocardio, (2002), 3 pp. 154-63
[18]
De Lemos JA, McGuire DK, Drazner MH..
B-type natriuretic peptide in cardiovascular disease..
Lancet, (2003), 362 pp. 316-22
[19]
Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, et al..
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely descompensated congestive heart failure: the PRECEDENT study..
Am Heart J, (2002), 144 pp. 1102-8
[20]
Burger AJ, Elkayam U, Neibaur MT, Hanght H, Ghali J, Horton DP, et al..
Comparison of the occurrence of ventricular arrhythmias in patients with acutely descompensated congestive heart failure receiving dobutamine versus nesiritide therapy..
Am J Cardiol, (2001), 88 pp. 35-9
[21]
Royuela N, Gómez I, González S, Vázquez JA..
Fármacos inotrópicos positivos en la insuficiencia cardíaca..
Medicine, (2001), 81 pp. 1987-93
[22]
Stevenson LW..
Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: Inotropic Infusions during hospitalization..
Circulation, (2003), 108 pp. 367-72
[23]
O'Connor CM, Gaths WA, Uretsky BF, Adams KF, Mc Nulty SE, Grossman SH, et al..
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST)..
Am Heart J, (1999), 138 pp. 78-86
[24]
Felker GM, O'Connor CM..
Inotropic therapy for heart failure: an evidence based approach..
Am Heart J, (2001), 142 pp. 393-401
[25]
Reinhart K, Sakka SG, Meier-Hellmann A..
Haemodynamic management of a patient with septic shock. Review..
Eur J Anaesthesiol, (2000), 17 pp. 6-17
[26]
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R..
A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure..
N Engl J Med, (1989), 320 pp. 677-83
[27]
Simonton CA, Chatterjee K, Cody RY..
Milrinone in congestive heart failure: Acute and chronic hemodynamics and clinical evaluation..
J Am Coll Cardiol, (1985), 6 pp. 453-9
[28]
The Digitalis Investigation Group..
The effects of digoxin on mortality and morbidity in patients with heart failure..
N Engl J Med, (1997), 336 pp. 525-33
[29]
Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol. 1995;26 Suppl 1:45-51.
[31]
Follath F, Cleland JF.J, Just H, Papp JG.Y, Scholz H, Peuhkurinen K, et al..
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial..
Lancet, (2002), 360 pp. 196-202
[32]
Moiseyev VS, Poder P, Andrejevs N..
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized placebo-controlled, double-blind study (RUSSLAN)..
Eur Heart J, (2002), 23 pp. 1422
[33]
Lilleberg J, Sundberg S, Häyhä M..
Haemodynamic dose-efficacy of levosimendan in health volunteers..
Eur J Clin Pharmacol, (1994), 47 pp. 267-74
[34]
Hall D, Zeitler H, Rudolph W..
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure..
J Am Coll Cardiol, (1992), 20 pp. 1549-55
[35]
Shibata MC, Flather MD, Wang D..
Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure..
Eur J Heart Fail, (2001), 3 pp. 351-7
[36]
Intraaortic ballon pumping in congestive heart failure. Pathophysiology, diagnosis and comprehensive approach to management. New York: Spring-Verlag; 1994. p. 522-47.
[37]
Rose E, Gelinjs A, Moskowitz A, Heitjan DF, Stevenson LW, Dembitsky W, et al..
Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long-term mechanical left ventricular assistance for end-stage heart failure..
N Engl J Med, (2001), 345 pp. 1425-43
[38]
Copeland JG, Smith RG, Arabia FA, Nolan PE, Sethi GK, Tsau PH, et al..
Cardiac replacement with a total artificial heart as a bridge to transplantation..
N Engl J Med, (2003), 351 pp. 859-67
